Pharma marketers are producing plenty of exceptional creative work in the DTC realm. There are also plenty that prompt quick checks to make sure that one hasn’t inadvertently clicked over to The Onion.
Warning letters most often stem from missing risk information
Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused
FDA letter focuses on UCLA claims about an unapproved diagnostic
March 10, 2015
7:32 pm
The agency’s Office of Prescription Drug Promotion said a website indicated safety and effectiveness of a diagnostic tool that has not been approved by the FDA.
Five things for pharma marketers to know: Tuesday, March 10
HCV drugs and other specialty medications drove a 13% increase in last year’s prescription spending, the CBO overestimated just how much healthcare reform would cost, and an FDA panel voted 17-0 in favor of Kythera’s drug that can reduce double chins.
The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.